Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Year End Trading Update

Cambridge Cognition Holdings plc, (AIM: COG), a specialist in the development and marketing of computerised tests for detection and monitoring of neuropsychological disorders, is pleased to announce that it has made significant progress with its commercial operations and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m including upfront payments and revenues to be recognized in the current year and through to 2017.

The potential for these contracts was highlighted in the interim results and they ensure that, despite increasing investment in both healthcare technology development and commercial infrastructure in the USA, the outturn for this year should be similar to 2014 and provide a strong contracted revenue base for the next fiscal year. Accordingly 2016 is expected to be a year of material growth as the Company continues to make significant commercial and technological advances.

Commenting on the results Steven Powell, Chief Operating Officer, said:

"We are pleased to have made significant progress in our pharmaceutical clinical trials business and these contracts provide a strong foundation for continued growth in 2016."

Enquiries: